Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 9/2023

Open Access 16-06-2023 | Breast Cancer | CLINICAL GUIDES IN ONCOLOGY

SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)

Authors: Francisco Ayala de la Peña, Silvia Antolín Novoa, Joaquín Gavilá Gregori, Lucía González Cortijo, Fernando Henao Carrasco, María Teresa Martínez Martínez, Cristina Morales Estévez, Agostina Stradella, María Jesús Vidal Losada, Eva Ciruelos

Published in: Clinical and Translational Oncology | Issue 9/2023

Login to get access

Abstract

Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. Thanks to the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages, despite the COVID-19 pandemic possibly having impacted these numbers (not yet quantified). In recent years, locoregional and systemic therapies are increasingly being directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibody–drug conjugates have also improved outcomes in some patient subgroups. This clinical practice guideline is based on a systematic review of relevant studies and on the consensus of experts from GEICAM, SOLTI, and SEOM.
Literature
1.
Sociedad Española de Oncología Médica (SEOM), Red Española de Registros del Cáncer (REDECAN). Las cifras del cáncer en España (2022). In: https://​seom.​org/​images/​LAS_​CIFRAS_​DEL_​CANCER_​EN_​ESPANA_​2022.​pdf.​ Accessed 10 Nov 2022.
2.
Bosch G, Posso M, Louro J, Roman M, Porta M, Castells X, et al. Impact of the COVID-19 pandemic on breast cancer screening indicators in a Spanish population-based program: a cohort study. Elife. 2022;11:1–16.CrossRef
3.
Khan AR, Khan S, Zimmerman V, Baddour LM, Tleyjeh IM. Quality and strength of evidence of the Infectious Diseases Society of America clinical practice guidelines. Clin Infect Dis. 2010;51:1147–56.PubMedCrossRef
4.
Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-major changes in the american joint committee on cancer eighth edition cancer staging manual. Cancer J Clin. 2017;67:290–303.CrossRef
5.
Perry N, Broeders M, de Wolf C, Tornberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann Oncol. 2007;19:614–22.PubMedCrossRef
6.
Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46:1296–316.PubMedCrossRef
7.
López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P. Cardio-onco-hematology in clinical practice. Position paper recommendations. Rev Esp Cardiol. 2017;70(6):47.
8.
Louie RJ, Tonneson JE, Gowarty M, Goodney PP, Barth RJ, Rosenkranz KM. Complete blood counts, liver function tests, and chest x-rays as routine screening in early-stage breast cancer: value added or just cost? Breast Cancer Res Treat. 2015;154:99–103.PubMedCrossRef
9.
Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011;20:491–4.PubMedCrossRef
10.
Koolen BB, Vrancken Peeters MJTFD, Aukema TS, Vogel VW, Oldenburg HSA, Hage JA. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: Comparison with conventional imaging techniques. Breast Cancer Res Treat. 2012;131:117–26.PubMedCrossRef
11.
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (Ed.). WHO Classification of Tumours of the Breast. World Health Organization Classification of tumours. Lyon, France; International Agency for Research on Cancer; 2012.
12.
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S. The 2019 world health organization classification of tumours of the breast. Histopathology. 2020;77:181–5.PubMedCrossRef
13.
Allison KH, Hammond EH, Dowsett M, McKermin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346–66.PubMedCrossRef
14.
Wolff AC, McShane LM, Hammond MEH, Allison KH, Fitzgibbons P, Press MF. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142:1364–82.PubMedCrossRef
15.
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S. Assessment of Ki67 in breast cancer: updated recommendations from the international ki67 in breast cancer working group. JNCI J Natl Cancer Inst. 2021;113:808–19.PubMedCrossRef
16.
Denkert C, Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50.PubMedCrossRef
17.
Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol. 2017;7:156.PubMedPubMedCentralCrossRef
18.
Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N. St. Gallen/Vienna 2019: A brief summary of the consensus discussion on the optimal primary breast cancer treatment. Breast Care (Basel). 2019;(14):103–10.
19.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111–21.PubMedPubMedCentralCrossRef
20.
Piccart M, Van’t Veer L, Poncet C, Lopes Cardozo J, Delaloge S, Pierga J, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22:476–88.PubMedCrossRef
21.
Kevin Kalinsky MD, Barlow WE. 21- gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336–47.PubMedCrossRef
22.
Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. Lancet Oncol. 2022;25:1–5.
23.
24.
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T et al. Assessment of a genomic assay in patients with ERBB2-positive breast cancer following neoadjuvant trastuzumab-based chemotherapy with or without Pertuzumab. JAMA Oncol. 2023;27:e230187. https://​doi.​org/​10.​1001/​jamaoncol.​2023.​0187.CrossRef
25.
26.
Kimball CC, Nichols CI, Vose JG, Peled AW. Trends in lumpectomy and oncoplastic breast conserving surgery in the US, 2011–2016. Ann Surg Oncol. 2018;25:3867–73.PubMedCrossRef
27.
Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, et al. Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg. 2015;150:778–86.PubMedPubMedCentralCrossRef
28.
Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates Thompson SA, et al. Operative and oncologic outcomes in 9861 patients with operable breast cancer: single-institution analysis of breast conservation with oncoplastic reconstruction. Ann Surg Oncol. 2016;23:3190–8.PubMedCrossRef
29.
Jonczyk MM, Jean J, Graham R, Chatterjee A. Surgical trends in breast cancer: a rise in novel operative treatment options over a 12 year analysis. Breast Cancer Res Treat. 2019;173(2):267–74.PubMedCrossRef
30.
Burstein HJ, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P, et al. Estimating the benefits of therapy for early-stage breast cancer: The St. Gallen international consensus guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30:1541–57.PubMedCrossRef
31.
Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JRD, et al. Management of hereditary breast cancer: american society of clinical oncology, american society for radiation oncology, and society of surgical society of surgical oncology guideline. J Clin Oncol. 2020;38:2080–106.PubMedCrossRef
32.
Giuliano AE, Ballman KV. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318:918–26.PubMedPubMedCentralCrossRef
33.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol Elsevier. 2014;15:1303–10.CrossRef
34.
Bernet L, Piñero A, Martínez M, Sicart SV, Algara M, Palomares E. Consenso de la Sociedad Española de Senología y Patología Mamaria (SESPM) sobre la biopsia selectiva del ganglio centinela (BSGC) y el manejo axilar en el cáncer de mama (2022). Rev Senol y Patol Mamar. 2022;35:243–59.
35.
Simons JM, Nijnatten TJA, CC P. Diagnostic accuracy of different surgical procedures for axillary staging after neoadjuvant systemic therapy in node-positive breast cancer: a systematic review and meta-analysis. Ann Surg. 2019;269:432–42.PubMedCrossRef
36.
Banys-Paluchowski M, Gasparri ML, Boniface J, Gentilini O, Stickeler E, Hartmann S, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. Cancers. 2021;13(7):1.CrossRef
37.
Shah C, Al-Hilli Z, Vicini F. Advances in breast cancer radiotherapy: implications for current and future practice. JCO Oncol Pr. 2021;17:697–706.
38.
Shah C, Bauer-Nilsen K, McNulty RH, Vicini F. Novel radiation therapy approaches for breast cancer treatment. Semin Oncol. 2020;47:209–16.PubMedCrossRef
39.
Brunt AM, Haviland JS, Wheatley DA. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicenter, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613–26.CrossRef
40.
Kunkler IH, Chir B, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in early breast cancer. N Engl J Med. 2023;388:585–94.PubMedCrossRef
41.
42.
Andre F, Ismaila N, K A. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:1816–34.PubMedCrossRef
43.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A Multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRef
44.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.PubMedCrossRef
45.
Cardoso F, Van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717–29.PubMedCrossRef
46.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005–14.PubMedPubMedCentralCrossRef
47.
Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh I-T, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11:55–65.PubMedCrossRef
48.
Lænkholm A-V, Jensen M-B, Eriksen JO, Rasmussen BB, Knoop AS, Buckingham W, et al. PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for hormone receptor-positive early breast cancer. J Clin Oncol. 2018;36:735–40.PubMedCrossRef
49.
Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. Br J Cancer. 2013;109:2959–64.PubMedPubMedCentralCrossRef
50.
Kalinsky K, Barlow WE, Gralow J, Meric-Bernstam F, Albain K, Hayes DF. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336–47.PubMedPubMedCentralCrossRef
51.
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol. 2014;25:339–45.PubMedCrossRef
52.
Smith I, Robertson J, Kilburn L, Wilcox M, Evans A, Holcombe C, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21:1443–54.PubMedPubMedCentralCrossRef
53.
Bradley R, Burrett J, Clarke M, Davies C, Duane F, Evans V, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: Patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52.CrossRef
54.
Lohrisch C, Paltiel C, Gelmon K. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2006;24:4888–94.PubMedCrossRef
55.
Early Breast Cancer Trialists. Collaborative group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.CrossRef
56.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805–16.PubMedPubMedCentralCrossRef
57.
58.
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122–37.PubMedPubMedCentralCrossRef
59.
Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, LHRH-agonists in Early Breast Cancer Overview group, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369:1711–23.PubMedCrossRef
60.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365:60–2.PubMedCrossRef
61.
Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, BIG 1-98 Collaborative Group, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361:766–76.PubMedCrossRef
62.
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM-K, Liefers G-J, et al. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10 year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1211–20.PubMedCrossRef
63.
Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol. 2005;23:5138–47.PubMedCrossRef
64.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–92.PubMedCrossRef
65.
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. The Lancet. 2005;366:455–62.CrossRef
66.
Corona SP, Roviello G, Strina C. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. Breast. 2019;46:19–24.PubMedCrossRef
67.
Zhang Y, Schroeder BE, Jerevall PL. A novel Breast Cancer Index for prediction of distant recurrence in HR+ early-stage breast cancer with one to three positive nodes. Clin Cancer Res. 2017;23:7217–24.PubMedCrossRef
68.
Sgroi DC, Sestak I, Cuzick J. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013;14:1067–76.PubMedPubMedCentralCrossRef
69.
Bartlett JMS, Sgroi DC, Treuner K. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the adjuvant tamoxifen-to offer more? (aTTom) trial. Ann Oncol. 2019;30:1776–83.PubMedPubMedCentralCrossRef
70.
Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:2062–81.PubMedCrossRef
71.
Johnston S, Harbeck N, Hegg R. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987–98.PubMedPubMedCentralCrossRef
72.
Andrew Tutt NJ, MB, Ch B JEG. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.PubMedCrossRef
73.
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: The St Gallen international expert consensus conference on the primary therapy of early breast cancer. Ann Oncol. 2017;28:1700–12.PubMedPubMedCentralCrossRef
74.
Nitz U, Gluz O, Huober J. Final analysis of the prospective WSGAGO EC-doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2017;28:2899.PubMedCrossRef
75.
Samuel JA, Wilson JW, Bandos H. Abstract S3–02: nSABP B-36: a randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of Adriamycin and cyclophosphamide (AC) in patients (pts) with node negative breast cancer. Cancer Res. 2015;75:3–02.CrossRef
76.
Jones S, Holmes FA, O’Shaughnessy J. Shaughness. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7 year follow-up of US. J Clin Oncol. 2009;27:1177–83.PubMedCrossRef
77.
Early Breast Cancer Trialists. Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:1440–52.CrossRef
78.
Peto R, Davies C, J G,. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of longterm outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–44.PubMedCrossRef
79.
Eggemann H, Ignatov A, Smith BJ. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137:465–70.PubMedCrossRef
80.
Korde LA, Zujewski JA, Kamin L, Sousa B, Moser E, Cardoso F. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114–22.PubMedPubMedCentralCrossRef
81.
Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol. 2013;717:71–83.PubMedCrossRef
82.
Gianni L, Baselga J, Eiermann W. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable breast cancer. J Clin Oncol. 2009;27:2474–81.PubMedCrossRef
83.
Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer J-U, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.PubMedCrossRef
84.
Dowsett M, Ellis MJ, Dixon JM, Gluz O, Robertson J, Kates R, et al. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic. NPJ Breast Cancer. 2020;6:21.PubMedPubMedCentralCrossRef
85.
Masuda N, Sagara Y, Kinoshita T. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13:345–52.PubMedCrossRef
86.
Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006–03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23:3069–74.PubMedCrossRef
87.
Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29:2342–9.PubMedPubMedCentralCrossRef
88.
Prat A, Galvan P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, et al. Prediction of response to neoadjuvant chemotherapy using core needle biopsy samples with the prosigna assay. Clin Cancer Res. 2016;22:560–6.PubMedCrossRef
89.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.PubMedCrossRef
90.
Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.PubMedCrossRef
91.
Swain SM, Miles D, Kim SB, Im Y, Im S, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 519–30.
92.
Voort A, Ramshorst M, Werkhoven E, Mandjes I, Kemper I, Vulink A, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): a randomized phase 3 trial. JAMA Oncol. 2021;7:978–84.PubMedCrossRef
93.
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278–84.PubMedCrossRef
94.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.PubMedPubMedCentralCrossRef
95.
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205.PubMedPubMedCentralCrossRef
96.
Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744–52.PubMedPubMedCentralCrossRef
97.
Inno A, Barni S, Ghidini A. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;173:247–54.PubMedCrossRef
98.
Niraula S, Gyawali B. Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;173:103–9.PubMedCrossRef
99.
Tolaney SM, Guo H, Pernas S. Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2019;37:1868–75.PubMedPubMedCentralCrossRef
100.
Piccart M, Procter M, Fumagalli D, De Azambuja E, Clark E, Ewer MS, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol. 2021;39:1448–57.PubMedCrossRef
101.
102.
Arlene MB, Mansi J. Final efficacy results of neratinib in HER2-positive hormone receptorpositive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2021;21:80–91.CrossRef
103.
Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.CrossRef
104.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours [Letter]. Nature. 2000;406:747–52.PubMedCrossRef
105.
106.
An X, Lei X, Huang R. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: a single-center study and a meta-analysis of the published literature. Cancer. 2020;126:3837–46.PubMedCrossRef
107.
Poggio F, Bruzzone M, Ceppi M, Pondé N, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and metaanalysis. Ann Oncol. 2018;29:1497–508.PubMedCrossRef
108.
Geyer C, Sikov W, Huober J, Rugo H, Wolmark N, O’Shaughnessy J, et al. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022;33:384–94.PubMedCrossRef
109.
Schmid P, Cortes J, Dent R. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386:556–67.PubMedCrossRef
110.
Mittendorf EA, Zhang H, Barrios CH. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double- blind, phase 3 tri. Lancet. 2020;396:1090–100.PubMedCrossRef
111.
Mackelenbergh M, Seither F, Möbus V, O’Shaughnessy J, Martin M, Joensuu H, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Eur J Cancer. 2022;166:185–201.PubMedCrossRef
112.
113.
Barnadas A, Algara M, Cordoba O, Casas A, Gonzalez M, Marzo M, et al. Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). Clin Transl Oncol. 2018;20:687–94.PubMedCrossRef
114.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220.PubMedCrossRef
115.
NCCN Guidelines. Version 2.2021. Invasive Breast Cancer. 2021.
Metadata
Title
SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
Authors
Francisco Ayala de la Peña
Silvia Antolín Novoa
Joaquín Gavilá Gregori
Lucía González Cortijo
Fernando Henao Carrasco
María Teresa Martínez Martínez
Cristina Morales Estévez
Agostina Stradella
María Jesús Vidal Losada
Eva Ciruelos
Publication date
16-06-2023
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 9/2023
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-023-03215-4

Other articles of this Issue 9/2023

Clinical and Translational Oncology 9/2023 Go to the issue

CLINICAL GUIDES IN ONCOLOGY

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

CLINICAL GUIDES IN ONCOLOGY

SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

CLINICAL GUIDES IN ONCOLOGY

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)

Correction

Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

EDITORIAL

SEOM 2022 clinical guidelines

Correction

Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits